Mydecine announces raising $1,693,434.60 in addition to gross proceeds of $333,333.35 announced on March 22, 2022.
Wesana Health Reports Q4 2021 Financial Results and Provides Subsequent Period Highlights
Wesana reports its Q4 2021 financial results and announces closing of a financing.
Optimi Health Granted Amendment To Controlled Substances Dealer’s Licence
Optimi Health announces receiving amendment to Health Canada's Dealer's License that will allow expand cultivation and research use of psilocybin and psilocin.
Awakn Life Sciences Reports Fiscal Fourth Quarter and Fiscal Year January 31, 2022, Results
Awakn Life Sciences reports fourth quarter and full-year results for its fiscal year ending January 31, 2022. Annual revenues of CAD$236,037.
Incannex Completes Loyalty Option Program to Raise A$23.6M; Current Cash at Bank is Approximately A$40.0M
Incannex Healthcare announces a "shareholder loyalty option" to raise A$23.6 million (US$16.5 million). For every two shares purchased, investors will receive a "piggyback option".
Optimi Health Opens Canada’s Largest GMP-Grade Licensed Psilocybin Cultivation Facility
Optimi Health announces the opening of Canada's largest GMP-grade psilocybin cultivation operating, including a 10,000 square foot production facility.
Field Trip Health Ltd. Announces Intention to Separate the Field Trip Discovery and Field Trip Health Divisions Into Two Independent Public Companies
Field Trip announces its corporate decision to separate Field Trip Health and Field Trip Discovery into separate companies.
TRYP THERAPEUTICS DOSES FIRST PATIENT IN PHASE II PSILOCYBIN-ASSISTED THERAPY CLINICAL TRIAL
Tryp Therapeutics announces initial patient enrollment in its Phase II clinical trial of a psilocybin-based compound (TRP-8802) for Binge Eating Disorder.
Is The Psychedelic Drug Industry Entering A New Phase?
Several major new deals in the psychedelics industry already in 2022 suggest that the industry could be moving on to its next phase of evolution.
Terran Biosciences announces licensing deal with Sanofi for two late-stage CNS pipeline assets
Private psychedelics company, Terran Biosciences announces a drug development partnership with Sanofi S.A. for the development and commercialization of two late-stage CNS drugs.
TRYP THERAPEUTICS INC. Announces Amendment to Terms of Private Placement and Closing of $3,000,000 Second Tranche
Tryp Therapeutics closes the second tranche of its recently announced private placement for gross proceeds of CAD$3 million. Units are priced at CAD$0.15.
Psychedelic Drug Patenting: Still Only Scratching The Surface
Dozens of psychedelic drugs to research. Several "generations" of R&D ahead. To say that we're early in the game with psychedelic drug research is an understatement.
